Piperazine derivatives useful as CCR5 antagonists

US7384944B2 · kind B2 · utility

Assignee

• SCHERING CORPORATION · US

Inventors

• Bahige M. Baroudy · Westfield, US
• John W. Clader · Cranford, US
• Hubert Josien · Hoboken, US
• Stuart W. McCombie · Caldwell, US
• Brian McKittrick · New Vernon, US
• Michael Miller · Scotch Plains, US
• Bernard R. Neustadt · West Orange, US
• Anandan Palani · Bound Brook, US
• Elizabeth M. Smith · Verona, US
• Ruo Steensma · Weehawken, US
• Jayaram R. Tagat · Westfield, US
• Susan F. Vice · Mountainside, US
• Mark Laughlin · Edison, US
• Eric J. Gilbert · Scotch Plains, US
• Marc A. Labroli · West Point, US

Key dates

• Filing date: Sep 23, 2003
• Grant date: Jun 10, 2008
• Expiry date: Aug 15, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The use of CCR5 antagonists of the formulaor a pharmaceutically acceptable salt thereof, wherein